Inventor · disambiguated record
John Hatcher
Also filed as: HATCHER JOHN · HATCHER JOHN M
19 granted patents·12 pending applications·5 citations·filing 2016–2025
87Inventor score
Top patents by PatentIndex Score
31 records- 0180US10913744B2LRRK2 inhibitors and methods of making and using the sameDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 9, 2021·3 cites·21 claims
- 0277US11542251B2IRAK degraders and uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Jan 3, 2023·2 cites·20 claims
- 0373US11858897B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2021·Granted Jan 2, 2024·0 cites·7 claims
- 0469US2023365620A1Cyclin-dependent kinase inhibitors and methods of useDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 0568US12233128B2Degraders that target ALK and therapeutic uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 25, 2025·0 cites·7 claims
- 0667US11066363B2Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2019·Granted Jul 20, 2021·0 cites·6 claims
- 0765US2025270252A1Cyclin-dependent kinase degraders and methods of useDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0863US11945816B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
- 0963US2020369715A1Cyclin-dependent kinase inhibitors and methods of useDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1061US2024391899A1Potent and selective inhibitors of irak4DANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1160US10508082B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2016·Granted Dec 17, 2019·0 cites·17 claims
- 1260US2021115055A1Lrrk2 inhibitors and methods of making and using the sameDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1359US12497398B2Potent and selective covalent inhibitors of serine-arginine protein kinase (SRPK) 1 and SRPK2 and uses thereofDANA FARBER CANCER INST INC·Filed 2021·Granted Dec 16, 2025·0 cites·20 claims
- 1459US2024308982A1Degraders of wild-type and mutant forms of lrrk2 and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1558US2024336643A1Bifunctional compounds that degrade alk and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1655US11186574B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 30, 2021·0 cites·20 claims
- 1755US2023295167A1Potent and selective inhibitors of her2DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1854US2023137932A1Cyano-pyrimidine inhibitors of egfr/her2DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1953US12325725B2Cyclin-dependent kinase degraders and methods of useDANA FARBER CANCER INST INC·Filed 2019·Granted Jun 10, 2025·0 cites·13 claims
- 2053US2024043405A1Potent and selective irreversible inhibitors of irak1DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2153US2023158157A1Potent and selective degraders of alkDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2251US12410194B2Potent and selective azaindole inhibitors of CDK8 and CDK19DANA FARBER CANCER INST INC·Filed 2020·Granted Sep 9, 2025·0 cites·27 claims
- 2350US12157741B2Macrocyclic inhibitors of DYRK1ADANA FARBER CANCER INST INC·Filed 2019·Granted Dec 3, 2024·0 cites·33 claims
- 2448US12157738B2Macrocyclic inhibitors of ALK, TRKA, TRKB, and ROS1DANA FARBER CANCER INST INC·Filed 2019·Granted Dec 3, 2024·0 cites·37 claims
- 2546US2021361774A1Degraders of wild-type and mutant forms of lrrk2DANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2643US12479847B2Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2DANA FARBER CANCER INST INC·Filed 2020·Granted Nov 25, 2025·0 cites·11 claims
- 2743US12275731B2Azaindole inhibitors of wild-type and mutant forms of LRRK2DANA FARBER CANCER INST INC·Filed 2019·Granted Apr 15, 2025·0 cites·20 claims
- 2841US11248007B2Inhibitors of MALT1 and uses thereofUNIV CORNELL·Filed 2018·Granted Feb 15, 2022·0 cites·20 claims
- 2941US10975055B2Inhibitors of interleukin-1 receptor-associated kinases and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 13, 2021·0 cites·20 claims
- 3038US10689366B2Compounds for MALT1 degredationUNIV CORNELL·Filed 2017·Granted Jun 23, 2020·0 cites·19 claims
- 3136US10711036B2MALT1 inhibitors and uses thereofUNIV CORNELL·Filed 2016·Granted Jul 14, 2020·0 cites·34 claims
Join the waitlist — get patent alerts
Get an alert when John Hatcher files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →